ImmuCell (NASDAQ:ICCC) Announces Quarterly Earnings Results

ImmuCell (NASDAQ:ICCC) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.32) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $7.63 million for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.

ImmuCell Stock Up 0.9%

ImmuCell stock opened at $6.46 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.21 and a quick ratio of 1.76. ImmuCell has a fifty-two week low of $4.28 and a fifty-two week high of $7.60. The firm has a fifty day moving average price of $6.37 and a two-hundred day moving average price of $6.09. The firm has a market cap of $58.44 million, a price-to-earnings ratio of 24.85 and a beta of 0.27.

Institutional Investors Weigh In On ImmuCell

Hedge funds have recently modified their holdings of the business. Mesirow Financial Investment Management Inc. lifted its stake in shares of ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after buying an additional 24,303 shares during the period. Steadtrust LLC increased its stake in ImmuCell by 79.1% during the fourth quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 25,070 shares during the period. Finally, Geode Capital Management LLC raised its holdings in ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after acquiring an additional 2,907 shares in the last quarter. 13.47% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 24th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, ImmuCell presently has an average rating of “Hold”.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.